Literature DB >> 10797558

Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.

I Lamensdorf1, G Eisenhofer, J Harvey-White, Y Hayakawa, K Kirk, I J Kopin.   

Abstract

3,4-Dihydroxyphenylacetaldehyde (DOPAL) has been reported to be a toxic metabolite formed by the oxidative-deamination of dopamine (DA) catalyzed by monoamine oxidase. This aldehyde is either oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase, an NAD-dependent enzyme or reduced to 3, 4-dihydroxyphenylethanol (DOPET) by aldehyde or aldose reductase. In the present study we examined whether levels of DOPAL are elevated by inhibition of the mitochondrial respiratory chain. Using inhibitors of mitochondrial complexes I, II, III and IV we found that inhibition of complex I and III increased levels of DOPAL and DOPET. Nerve growth factor-induced differentiation of PC12 cells markedly potentiated DOPAL and DOPET accumulation in response to metabolic stress. DOPAL was toxic to differentiated PC12 as well as to SK-N-SH cell lines. Because complex I dysfunction has been implicated in the pathogenesis of Parkinson's disease, the accumulation of DOPAL may explain the vulnerability of the dopaminergic system to complex I inhibition. The rapid appearance of DOPAL and DOPET after inhibition of complex I may be a useful early index of oxidative stress in DA-forming neurons. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797558     DOI: 10.1002/(SICI)1097-4547(20000515)60:4<552::AID-JNR14>3.0.CO;2-U

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  31 in total

1.  Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

Authors:  Lydia M Mexas; Virginia R Florang; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2011-04-14       Impact factor: 4.294

2.  Catechols in post-mortem brain of patients with Parkinson disease.

Authors:  D S Goldstein; P Sullivan; C Holmes; I J Kopin; M J Basile; D C Mash
Journal:  Eur J Neurol       Date:  2010-11-12       Impact factor: 6.089

3.  Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2015-02-25       Impact factor: 5.372

Review 4.  Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Clin Exp Nephrol       Date:  2011-05-25       Impact factor: 2.801

5.  Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture.

Authors:  G Gille; K Radad; H Reichmann; W-D Rausch
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

6.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).

Authors:  Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

7.  L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.

Authors:  Anthony Donsante; Patricia Sullivan; David S Goldstein; Lauren R Brinster; Stephen G Kaler
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

8.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Rachel Sullivan; Daniel J Gross; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2012-10-25       Impact factor: 5.372

9.  Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.

Authors:  David S Goldstein; Yunden Jinsmaa; Patti Sullivan; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

10.  Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.

Authors:  Yunden Jinsmaa; Virginia R Florang; Jennifer N Rees; David G Anderson; Stefan Strack; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2009-05       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.